David J Mazzo Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for David J Mazzo.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of David J Mazzo. David J Mazzo is Chief Executive Officer in Caladrius Biosciences, Inc. ($NBS) and Director in AVANIR PHARMACEUTICALS, INC. ($AVNR) and in EyePoint Pharmaceuticals, Inc. ($EYPT) and Director in pSivida Corp. ($PSDV) and Director in Neuralstem, Inc. ($CUR).
Latest Insider Trading Transactions of David J Mazzo
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AVNR, NBS, EYPT, SNCA
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 26 2021 | SNCA | Seneca Biopharma, ... | Mazzo David J | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
| Jan 15 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 1.56 | 5,936 | 9,260 | 299,505 | 305.4 K to 299.5 K (-1.94 %) |
| Jan 15 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 1.55 | 6,425 | 9,959 | 305,441 | 311.9 K to 305.4 K (-2.06 %) |
| Jan 15 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 1.55 | 21,787 | 33,770 | 311,866 | 333.7 K to 311.9 K (-6.53 %) |
| Jan 15 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Grant | A | 0.00 | 39,000 | 0 | 333,653 | 294.7 K to 333.7 K (+13.24 %) |
| Jan 12 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Option Exercise | A | 1.59 | 60,000 | 95,400 | 60,000 | |
| Jan 12 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 1.59 | 16,621 | 26,427 | 294,653 | 311.3 K to 294.7 K (-5.34 %) |
| Jan 12 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Grant | A | 0.00 | 119,000 | 0 | 311,274 | 192.3 K to 311.3 K (+61.89 %) |
| Jan 12 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 1.60 | 4,726 | 7,562 | 192,274 | 197 K to 192.3 K (-2.40 %) |
| Apr 07 2020 | SNCA | Seneca Biopharma, ... | Mazzo David J | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
| Jan 15 2020 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Option Exercise | A | 3.28 | 69,000 | 226,320 | 69,000 | |
| Jan 15 2020 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 3.38 | 6,382 | 21,571 | 186,382 | 192.8 K to 186.4 K (-3.31 %) |
| Jan 15 2020 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 3.28 | 6,246 | 20,487 | 192,764 | 199 K to 192.8 K (-3.14 %) |
| Jan 15 2020 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Grant | A | 0.00 | 46,000 | 0 | 199,010 | 153 K to 199 K (+30.06 %) |
| Jan 09 2020 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 2.83 | 4,522 | 12,797 | 153,010 | 157.5 K to 153 K (-2.87 %) |
| Oct 11 2019 | EYPT | EyePoint Pharmaceu ... | Mazzo David J | Option Exercise | M | 1.95 | 33,333 | 64,999 | 0 | ||
| Oct 11 2019 | EYPT | EyePoint Pharmaceu ... | Mazzo David J | Buy | M | 1.95 | 33,333 | 64,999 | 200,083 | 166.8 K to 200.1 K (+19.99 %) | |
| Sep 10 2019 | EYPT | EyePoint Pharmaceu ... | Mazzo David J | Option Exercise | M | 0.00 | 417 | 0 | 0 | ||
| Sep 10 2019 | EYPT | EyePoint Pharmaceu ... | Mazzo David J | Buy | M | 0.00 | 417 | 0 | 166,750 | 166.3 K to 166.8 K (+0.25 %) | |
| Jul 03 2019 | CUR | Neuralstem, Inc. | Mazzo David J | Director | Option Exercise | A | 0.30 | 187,510 | 56,272 | 187,510 | |
| Jun 27 2019 | EYPT | EyePoint Pharmaceu ... | Mazzo David J | Option Exercise | A | 2.65 | 40,000 | 106,000 | 40,000 | ||
| Jun 24 2019 | EYPT | EyePoint Pharmaceu ... | Mazzo David J | Option Exercise | M | 0.00 | 8,333 | 0 | 0 | ||
| Jun 24 2019 | EYPT | EyePoint Pharmaceu ... | Mazzo David J | Buy | M | 0.00 | 8,333 | 0 | 166,333 | 158 K to 166.3 K (+5.27 %) | |
| Apr 01 2019 | EYPT | EyePoint Pharmaceu ... | Mazzo David J | Option Exercise | M | 1.77 | 20,000 | 35,400 | 0 | ||
| Apr 01 2019 | EYPT | EyePoint Pharmaceu ... | Mazzo David J | Buy | M | 1.77 | 20,000 | 35,400 | 158,000 | 138 K to 158 K (+14.49 %) | |
| Jan 16 2019 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Option Exercise | A | 4.95 | 71,000 | 351,450 | 71,000 | |
| Jan 16 2019 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 0.00 | 6,301 | 0 | 151,405 | 157.7 K to 151.4 K (-4.00 %) |
| Jan 16 2019 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Grant | A | 0.00 | 47,000 | 0 | 157,706 | 110.7 K to 157.7 K (+42.45 %) |
| Jan 10 2019 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 4.64 | 4,478 | 20,778 | 110,706 | 115.2 K to 110.7 K (-3.89 %) |
| Sep 10 2018 | PSDV | EyePoint Pharmaceu ... | Mazzo David J | Director | Option Exercise | A | 0.00 | 417 | 0 | 417 | |
| Sep 10 2018 | PSDV | EyePoint Pharmaceu ... | Mazzo David J | Director | Option Exercise | A | 2.32 | 1,667 | 3,867 | 1,667 | |
| Jun 29 2018 | PSDV | EyePoint Pharmaceu ... | Mazzo David J | Director | Option Exercise | M | 0.00 | 17,500 | 0 | 0 | |
| Jun 29 2018 | PSDV | EyePoint Pharmaceu ... | Mazzo David J | Director | Buy | M | 0.00 | 17,500 | 0 | 138,000 | 120.5 K to 138 K (+14.52 %) |
| Jun 26 2018 | PSDV | EyePoint Pharmaceu ... | Mazzo David J | Director | Option Exercise | A | 0.00 | 8,333 | 0 | 8,333 | |
| Jun 26 2018 | PSDV | EyePoint Pharmaceu ... | Mazzo David J | Director | Option Exercise | A | 1.95 | 33,333 | 64,999 | 33,333 | |
| Jun 21 2018 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 8.64 | 16,091 | 139,026 | 109,453 | 125.5 K to 109.5 K (-12.82 %) |
| Jun 21 2018 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Grant | A | 8.64 | 33,300 | 287,712 | 125,544 | 92.2 K to 125.5 K (+36.10 %) |
| Apr 24 2018 | PSDV | EyePoint Pharmaceu ... | Mazzo David J | Director | Option Exercise | M | 1.13 | 120,000 | 135,600 | 0 | |
| Apr 24 2018 | PSDV | EyePoint Pharmaceu ... | Mazzo David J | Director | Buy | M | 1.13 | 120,000 | 135,600 | 120,500 | 500 to 120.5 K (+24,000.00 %) |
| Apr 10 2018 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Option Exercise | A | 0.00 | 33,300 | 0 | 33,300 | |
| Apr 10 2018 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Option Exercise | A | 0.00 | 33,300 | 0 | 33,300 | |
| Jan 10 2018 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Option Exercise | A | 3.79 | 50,000 | 189,500 | 20,000 | |
| Jan 10 2018 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 0.00 | 4,462 | 0 | 92,244 | 96.7 K to 92.2 K (-4.61 %) |
| Jan 10 2018 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Grant | A | 0.00 | 33,300 | 0 | 96,706 | 63.4 K to 96.7 K (+52.52 %) |
| Dec 19 2017 | PSDV | pSivida Corp. | Mazzo David J | Director | Option Exercise | A | 0.00 | 17,500 | 0 | 17,500 | |
| Dec 19 2017 | PSDV | pSivida Corp. | Mazzo David J | Director | Option Exercise | A | 1.77 | 20,000 | 35,400 | 20,000 | |
| May 22 2017 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 5.13 | 17,778 | 91,201 | 56,551 | 74.3 K to 56.6 K (-23.92 %) |
| Jan 27 2017 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 3.87 | 761 | 2,945 | 75,019 | 75.8 K to 75 K (-1.00 %) |
| Jan 11 2017 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Option Exercise | A | 3.54 | 50,000 | 177,000 | 50,000 | |
| Jan 11 2017 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 3.54 | 4,758 | 16,843 | 75,780 | 80.5 K to 75.8 K (-5.91 %) |
| Jan 11 2017 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Grant | A | 0.00 | 33,300 | 0 | 80,538 | 47.2 K to 80.5 K (+70.49 %) |
| Dec 14 2016 | PSDV | pSivida Corp. | Mazzo David J | Director | Option Exercise | A | 3.49 | 30,000 | 104,700 | 30,000 | |
| Nov 10 2016 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 4.12 | 457 | 1,883 | 47,238 | 47.7 K to 47.2 K (-0.96 %) |
| Sep 30 2016 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Option Exercise | A | 4.77 | 50,919 | 242,884 | 50,919 | |
| Aug 12 2016 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 5.40 | 457 | 2,468 | 47,695 | 48.2 K to 47.7 K (-0.95 %) |
| May 02 2016 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 0.68 | 4,545 | 3,091 | 458,839 | 463.4 K to 458.8 K (-0.98 %) |
| Jan 27 2016 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Option Exercise | A | 0.63 | 350,000 | 220,500 | 350,000 | |
| Jan 27 2016 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 0.63 | 21,094 | 13,289 | 463,384 | 484.5 K to 463.4 K (-4.35 %) |
| Jan 27 2016 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Grant | A | 0.00 | 212,800 | 0 | 484,478 | 271.7 K to 484.5 K (+78.33 %) |
| Dec 04 2015 | PSDV | pSivida Corp. | Mazzo David J | Director | Option Exercise | A | 4.09 | 30,000 | 122,700 | 30,000 | |
| Aug 18 2015 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Buy | P | 1.40 | 20,000 | 27,922 | 259,543 | 239.5 K to 259.5 K (+8.35 %) |
| Jun 04 2015 | NBS | Caladrius Bioscien ... | Mazzo David J | Chief Executive Off ... | Grant | A | 0.00 | 80,000 | 0 | 239,543 | 159.5 K to 239.5 K (+50.14 %) |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | Mazzo David J | Director | Buy | P | 15.59 | 1,000 | 15,590 | 7,435 | 6.4 K to 7.4 K (+15.54 %) |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | Mazzo David J | Director | Grant | A | 0.00 | 6,435 | 0 | 6,435 | 0 to 6.4 K |
Page: 1